Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...

Nosis Bio, a startup developing new ways to deliver RNA therapies to specific cells, has struck partnerships with two pharma ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Bureaucracy, aversion to risk, high taxes are blamed for why Japan lags behind in the start-up scene. Read more at ...

U.S. President Donald Trump has issued a memorandum directing federal agencies to restrict inbound and outbound investments ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Kyowa Kirin Co (KYKOF – Research Report), with a ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.